Anlotinib Versus Chemotherapy as a Third-Line or Further Treatment for Advanced Small Cell Lung Cancer

被引：0
|
作者：
Wang, Y. [1 ]
Ling, X. [1 ]
Cao, S. [1 ]
Li, J. [1 ]
Zhou, Y. [1 ]
Nie, W. [1 ]
Zhong, H. [1 ]
机构：
[1] Shanghai Chest Hosp, Dept Pulm, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
small cell lung cancer; Anlotinib; chemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P48.11
引用
收藏
页码：S504 / S504
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
    Zhu, Qiuyan
    Ni, Ronghua
    Guan, Xin
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (08) : 1782 - 1789
  • [2] COST-EFFECTIVENESS ANALYSIS OF ANLOTINIB AS A THIRD-LINE OR FURTHER TREATMENT IN ADVANCED NON-SMALL LUNG CANCER
    Huang, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S48 - S48
  • [3] Third-line chemotherapy for small cell lung cancer
    de Jong, Wouter K.
    ten Hacken, Nick H. T.
    Groen, Harry J. M.
    [J]. LUNG CANCER, 2006, 52 (03) : 339 - 342
  • [4] Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study
    Zhang, Wenjie
    Zhang, Chufeng
    Yang, Shengjie
    Chen, Qing
    Wang, Chen
    Guo, Qisen
    [J]. FUTURE ONCOLOGY, 2021, 17 (31) : 4091 - 4099
  • [5] Third-line chemotherapy for small cell lung cancer (SCLC)
    de Jong, W
    ten Hacken, N
    Groan, H
    [J]. LUNG CANCER, 2005, 49 : S317 - S318
  • [6] Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer
    Tatli, Ali Murat
    Arslan, Deniz
    Uysal, Mukremin
    Goksu, Sema Sezgin
    Gunduz, Seyda Gulenay
    Coskun, Hasan Senol
    Ozdogan, Mustafa
    Savas, Burhan
    Bozcuk, Hakan Sat
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (04) : 805 - 809
  • [7] Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
    Beninato, T.
    Manglaviti, S.
    Zattarin, E.
    Apollonio, G.
    Galli, E.
    Bini, M.
    Sposetti, C.
    Massa, G.
    Bottiglieri, A.
    Ganzinelli, M.
    Proto, C.
    Ferrara, R.
    Prelaj, A.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    De Braud, F. G. M.
    Garassino, M. C.
    Lo Russo, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1078 - S1078
  • [8] The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
    Zhai, Chongya
    Zhang, Xiaoling
    Ren, Lulu
    You, Liangkun
    Pan, Qin
    Pan, Hongming
    Han, Weidong
    [J]. FRONTIERS IN ONCOLOGY, 2021, 10
  • [9] THIRD-LINE CHEMOTHERAPY IN SMALL CELL LUNG CANCER: AN INTERNATIONAL ANALYSIS
    Simos, D.
    Sajjady, G.
    Sergi, M.
    Liew, M. S.
    Califano, R.
    Ho, C.
    Leighl, N. B.
    White, S.
    Summers, Y.
    Wheatley-Price, P.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 493 - 494
  • [10] A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second-or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer
    Wang, Hai-ying
    Chu, Jun-feng
    Zhao, Yan
    Tang, Hong
    Wang, Li-li
    Zhou, Meng-qiang
    Yan, Zheng
    Liu, Yan-yan
    Yao, Zhi-hua
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3827 - 3834
12345